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Abstract
Background: Assessment of liver function is critical in hepatocellular carcinoma (HCC) patient management. We
evaluated parameters of [99mTc] sulfur colloid (SC) SPECT/CT liver uptake for association with clinical measures of
liver function and outcome in HCC patients.
Methods: Thirty patients with HCC and variable Child-Turcotte-Pugh scores (CTP A5-C10) underwent [99mTc]SC
SPECT/CT scans for radiotherapy planning. Gross tumor volume (GTV), anatomic liver volume (ALV), and spleen were
contoured on CT. SC SPECT image parameters include threshold-based functional liver volumes (FLV) relative to
ALV, mean liver-to-spleen uptake ratio (L/Smean), and total liver function (TLF) ratio derived from the product of FLV
and L/Smean. Optimal SC uptake thresholds were determined by ROC analysis for maximizing CTP classification
accuracy. Image metrics were tested for rank correlation to composite scores and clinical liver function parameters.
Image parameters of liver function were tested for association to overall survival with Cox proportional hazard
regression.
Results: Optimized thresholds on SC SPECT were 58 % of maximum uptake for FLV, 38 % for L/Smean, and 58 % for
TLF. TLF produced the highest CTP classification accuracy (AUC = 0.93) at threshold of 0.35 (sensitivity = 0.88,
specificity = 0.86). Higher TLF was associated with lower CTP score: TLFA = 0.6 (0.4–0.8) versus TLFB = 0.2 (0.1–0.3),
p < 10−4. TLF was rank correlated to albumin and bilirubin (|R| > 0.63). Only TLF >0.30 was independently associated
with overall survival when adjusting for CTP class (HR = 0.12, 95 % CI = 0.02–0.58, p = 0.008).
Conclusions: SC SPECT/CT liver uptake correlated with differential liver function. TLF was associated with improved
overall survival and may aid in personalized oncologic management of HCC patients.
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Background
The accurate assessment of liver function is of critical
importance in the management of patients with hepato-
cellular carcinoma (HCC) [1]. The majority of patients
with HCC have associated chronic liver disease (viral
hepatitis, alcohol injury, or steatosis) [2] and resultant
cirrhosis that places patients at risk of morbidity and
mortality from liver-directed therapies [3–7]. Traditionally,
severity of chronic liver disease has been graded using the
Child-Turcotte-Pugh (CTP) classification system [8, 9], ori-
ginally designed over 50 years ago to estimate mortality in
patients with cirrhosis and portal hypertension prior to
undergoing surgical treatment of portal hypertension. The
CTP system [9] assigns points to 3 continuous objective
variables (serum bilirubin, albumin, and prothrombin time)
and 2 subjective variables (ascites and hepatic encephalop-
athy). These points are added together to generate a com-
posite score to assign patients into one of the three classes
with increasing liver dysfunction: A, B, or C.
While the CTP classification system has been shown
to be an independent prognostic factor, it has inherent
limitations that can under- or overestimate the degree of
liver dysfunction, such as empiric cutoff values, equal
weighting of variables, and challenges with the subjective
interpretation of ascites and encephalopathy [10]. More
recently, other prognostic models of cirrhosis have been
designed, including the model for end-stage liver disease
(MELD) score [11, 12] and its derivatives [10], that are
utilized for prioritization of liver transplantation. These
systems, however, were not specifically designed for pa-
tients with HCC, unlike the recently published albumin-
bilirubin (ALBI) grade [13]. Staging systems that incorp-
orate both tumor and liver function parameters for HCC
patients include the Barcelona Clinic Liver Cancer
(BCLC), Cancer of the Liver Italian Program (CLIP), and
Japan Integrated Scoring system (JIS) [14]. However, all of
these classification systems and models (including CTP
and MELD) still rely on traditional measures of liver func-
tion, only provide a global assessment of liver function,
and/or do not take into account spatial variations in
liver function [15]. Knowledge of this patient-specific
liver function heterogeneity may be valuable in the local
therapeutic management of HCC patients [16, 17].
Quantitative imaging of liver function holds promise
as an alternative to traditional measures of liver func-
tion, if properly validated. Diagnostic imaging of liver
function includes positron emission tomography (PET)
with [18F]fluorodeoxygalactose [18, 19] and dynamic
contrast-enhanced magnetic resonance imaging [20]
with gadoxetic acid [21] or gadoxetate disodium [22, 23].
Single photon emission computed tomography (SPECT)
of several radiotracers have been investigated as surro-
gates for liver function [18, 19, 21, 24], most notably
[99mTc] hepatobiliary iminodiacetic acid [25], [99mTc]
galactosyl-human serum albumin [24], and [99mTc] sul-
fur colloid (SC). The latter is a well-established FDA-
approved diagnostic tracer that images the reticuloendo-
thelial (Kupffer) cells of the liver and has been shown to
correlate with chronic liver disease severity and function
[26–29]. However, the reliability of quantitative molecular
imaging parameters as surrogates of global and regional
liver function and their relationship to conventional liver
function parameters remains unclear. Historical methods
of qualitatively or semi-quantitatively assessing SC distri-
bution with 2-D planar scintigraphy provided limited con-
trast and spatial resolution that relied on expert observer
interpretation. Subjective visual scoring of planar scintig-
raphy was ineffective in detecting variations in liver func-
tion [30], which highlights the critical need for more
sensitive tests with standardized quantitative parameters.
The evolution of combined SPECT/CT technology has
improved regional contrast between functional and non-
functional liver from tomographic image acquisition. It
has also increased the accuracy in local SC uptake esti-
mation from collimator-detector response modeling,
scatter correction, and CT-based attenuation correction,
resulting in distinct uptake patterns between patients with
differential liver function (Fig. 1). In this era of modern SC
SPECT/CT imaging, however, it is not known which im-
aging metrics are most closely associated with clinical liver
function and patient outcomes. The purpose of this study,
therefore, is to test measures of [99mTc]SC SPECT/CT
liver uptake for statistical association with traditional
clinical measures of liver function and survival in HCC
patients. Automatic SPECT region-of-interest definition
was first optimized to differentiate between CTP classes,
and then, SC SPECT/CT metrics were independently
correlated to clinical outcome as part of univariate
and multivariate analyses. In the absence of absolute
quantitative SPECT characterization, relative image in-
tensity ratios were constructed to quantify both mag-
nitude and volumetric extent of liver function.
Methods
Patient characteristics
After obtaining Institutional Review Board approval, 30
HCC patients (19 males, 11 females) with a median age of
67 years (range 43–84) were included in the study, from
2013 to 2015. Patients were selected for external beam
radiotherapy after multi-disciplinary assessment for suit-
ability and ineligibility for other liver-directed therapies.
Twenty-eight patients had unifocal HCC lesions, and
gross tumor volumes (GTV) ranged from 1–1573 cm3
(median 15 cm3). The majority of patients (71 %) had re-
ceived prior liver-directed therapy (LDT) for HCC and
presented with persistent disease, local recurrence, or
new HCC lesions, as defined by either contrast enhanced
CT or MRI. Prior LDTs included radiofrequency ablation
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(n = 7), transarterial chemoembolization (n = 15), radio-
embolization (n = 3), or bland embolization (n = 2), and
exactly half of all patients received more than one LDT.
The median time from the last LDT was 3 months
(range 1–35 months). All patients had underlying clin-
ically diagnosed cirrhosis, predominantly with either well-
compensated or mildly decompensated liver function: CTP
A (n = 16), CTP B (n = 12), and CTP C (n = 2), respectively
(range A5–C10). Cirrhosis was related to either hepatitis C
(n = 17), alcohol intake (n = 8), non-alcoholic fatty liver dis-
ease (n = 5), hepatitis B (n = 6), or a combination of these
factors (n = 7). A minority of patients presented with hep-
atic encephalopathy (n = 6) or ascites (n = 5).
CTP class was calculated using history and physical
examination findings, imaging results, and laboratory
data [8, 9]. Patients presented with a range of baseline
albumin (2.1–4.0 g/dL), bilirubin (0.3–2.4 mg/dL), and
international normalized ratios (INR) (0.9–5.8). Portal
hypertension was defined as clinical or radiographic evi-
dence of portal venous system varices/splenomegaly or
ongoing medical management for varices. Splenomegaly
was defined when the greatest oblique superior to infer-
ior dimension on sagittal CT scan was >15 cm.
SPECT/CT image acquisition, reconstruction, and
registration
All patients with a history of cirrhosis and/or prior liver-
directed therapy treated in our department from 2013 to
2015 underwent [99mTc]SC SPECT/CT scans prior to
definitive radiotherapy as part of their clinical care and
were reproducibly immobilized in treatment position.
SPECT/CT images were acquired on a Precedence™
(Philips Healthcare, Andover, MA) scanner comprising a
dual head gamma camera and 16 slice CT scanner.
Following the injection of 7 mCi (259 MBq) [99mTc]SC,
SPECT scans were acquired 15 min post-injection over a
fixed time-averaged frame (64 views, 20 s/view, 180° arc).
Emission images were corrected for scatter, collimator-
detector response, and attenuation using a tidal breathing
end-exhale position CT image. Reconstructions were
performed with the Astonish™ (Philips Healthcare,
Andover, MA) ordered subset expectation-maximization
(OSEM) iterative algorithm over 2 iterations and 16
subsets that included a 10-mm Hanning filter and
4.7 mm isotropic voxels.
Liver anatomy from the end-exhale attenuation correc-
tion CT acquired with each SPECT scan was registered
to the reference liver anatomy from the end-exhale re-
spiratory phase of a radiotherapy planning CT acquired
under free-breathing (n = 13), abdominal compression
(n = 10), or active breathing control (ABC™, Elekta Inc.,
Stockholm, Sweden) breath-hold conditions (n = 7).
Rigid registration between the planning CT and SPECT/
CT was performed in MIM 6.4™ (MIM Software Inc.,
Cleveland, OH) using built-in mutual information
methods. The resulting spatial transformations estimated
from CT-to-CT registration were applied to the respect-
ive SPECT images. Deformable registration techniques
between the radiotherapy planning CT and attenuation
correction CT were initially evaluated but did not provide
sufficiently improved liver registration accuracy, particu-
larly in the context of end-exhale CT scans and low spatial
resolution SPECT, to warrant their implementation for
this study.
CTP A6 CTP B7 












Fig. 1 Sulfur colloid SPECT/CT uptake patterns in hepatocellular carcinoma patients with different Child-Turcotte-Pugh score. Four patients are
shown with varying degrees of global liver uptake relative to spleen and regional uptake variation, which may be a consequence of their clinical
liver function status. Imaging can parameterize these uptake patterns and provide non-invasive longitudinal biomarkers of liver function. Color
scales have been normalized to spleen uptake to allow inter-patient comparison of liver uptake. Gross tumor is outlined in red where indicated
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SC SPECT metrics
Regions of interest such as the GTV, anatomic liver vol-
ume (ALV, defined as the liver minus GTV), and spleen
were defined on the planning CT, with the assistance of
contrast-enhanced CT scans as needed. On the spatially
aligned SC SPECT image, two relative metrics of func-
tional liver volume (FLV) and liver function magnitude
were calculated: the ratio of an uptake threshold-defined
functional volume to ALV and the ratio of mean liver
counts within the ALV to mean spleen counts (L/Smean).
These parameters did not rely on absolute quantitative
estimates of tracer activity concentration (MBq/mL). Ra-
tios of uptake in the liver versus spleen have been found
useful in prior reports [28] and assume that the majority
of SC uptake is in the liver and spleen, even in the pres-
ence of shunting to the bone marrow in cirrhotic pa-
tients. The FLV ratio represents a volumetric measure of
liver function, while L/Smean represents a global magni-
tude of liver function. A macroparameter calculated
from product of the FLV and L/Smean ratios, termed the
total liver function (TLF) ratio, is a measure of integral
liver function. These SC SPECT parameters were calcu-
lated by the following equations:
FLV ¼ fV=ALV ð1Þ
L=Smean ¼ I livermean=Ispleenmean ð2Þ
TLF ¼ FLV  L=Smean ð3Þ
The functional volume (fV) was defined by an image
intensity threshold as a percentage of maximum SC
SPECT image intensity within the ALV. The mean image
intensity (Imean) was also defined by a fixed threshold as
a percentage of maximum SC SPECT image intensity
within the ALV or the spleen. A range of image intensity
thresholds were tested, as described in the “Statistical
analysis” section. The ensemble of SC SPECT uptake
measures (FLV, L/Smean, TLF) is analogous to the quanti-
tative FDG PET parameters of metabolic tumor volume
(MTV), mean tumor uptake (SUVmean) or mean tumor-
to-blood ratio (T/Bmean), and total lesion glycolysis (TLG).
Statistical analysis
Optimal image thresholds for SC SPECT parameter as-
sociation with CTP classification (A vs. B/C class) were
interrogated by receiver-operator characteristic (ROC)
analysis. A range of image intensity thresholds to define
functional liver regions of interest, calculated as a per-
centage of maximum SC SPECT liver uptake from 20 to
70 % in increments of 2 %, were included in ROC ana-
lysis of FLV ratio, L/Smean ratio, and TLF ratio to
maximize the ROC area under the curve (AUC). The
maximum AUC image thresholds defined functional
liver regions of interest and the SC SPECT metrics for
all remaining statistical analysis. Significant differences
in Wilcoxon rank sum of ROC-optimized SC SPECT pa-
rameters were tested between CTP classes. Spearman
rank correlations between SC SPECT parameters and
clinical liver function parameters were tabulated for the
following categories: (1) composite liver function scoring
systems (CTP score, ALBI grade), (2) individual quanti-
tative liver function components (albumin, bilirubin,
INR), and (3) individual qualitative clinical liver function
components (encephalopathy, portal hypertension, asci-
tes, and splenomegaly). Qualitative components were
treated as binary categorical variables (yes/no).
Imaging and clinical parameters of liver function were
tested for association with overall survival. Continuous
variables were first dichotomized above and below a
threshold value that maximized accuracy of classification
under ROC with balanced sensitivity and specificity.
Univariate Cox proportional hazard regression was then
performed on all continuous and categorical variables.
Statistically significant variables that were not highly cor-
related were selected for multivariate Cox proportional
hazard regression to maximize model log-likelihood. For
this preliminary investigation in a limited patient cohort,
one imaging variable and one clinical variable were se-
lected. The simple multivariate model served to adjust for
the effect size of established clinical liver function scoring
systems (CTP, ALBI) with known association with overall
survival. All statistical calculations were performed in Ori-
ginPro 9.1™ (OriginLab Corporation, Northampton, MA),
and all hypothesis testing reported two-tailed p values.
Results
Figure 2 displays the ROC analysis for determination of
optimal SC SPECT image uptake thresholds and image
parameter for CTP class differentiation (A vs. B/C). As
image thresholds of percentage maximum SC SPECT
uptake were increased (Fig. 2a), the FLV ratio AUC in-
creased monotonically before reaching a global max-
imum at 58 %. The L/Smean ratio remained relatively
constant in its classification accuracy of CTP outside of
a global maximum at 38 %. The TLF ratio as a product
of FLV and L/Smean ratios maximized classification ac-
curacy at a threshold of 58 %. The optimal thresholds
for each parameter (58 % max SC SPECT uptake for FLV
and TLF ratios, 38 % max SC SPECT uptake for L/Smean)
defined a set of ROC curves in Fig. 2b, which show equal
increase in AUC from 0.87 to 0.93. Among these three
image parameters, the TLF ratio at the optimal 58 %
threshold was best at predicting CTP class with an AUC
of 0.93. For an operating point that equalizes specificity
and sensitivity, the optimal cutoff values were an FLV ratio
of 0.40 (sensitivity = 0.75, specificity = 0.71), L/Smean ratio
of 0.88 (sensitivity = 0.88, specificity = 0.86), and TLF ratio
of 0.35 (sensitivity = 0.88, specificity = 0.86).
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Table 1 lists the difference in the optimized image
threshold parameters between CTP classes. The FLV ratio
displayed the lowest sensitivity in median difference be-
tween CTP A and B/C patients, whereas the L/Smean ratio
showed the highest sensitivity in median difference but
also the highest intra-class quartile range. The TLF ratio
as their product demonstrated both high sensitivity in me-
dian difference but low variability in intra-class quartile
range, reflected in the lowest probability of a type I error.
From the optimized image thresholds, the FLV ratio,
L/Smean ratio, and TLF ratio were rank correlated to
clinical liver function parameters in Fig. 3. With decreas-
ing clinical liver function (increasing CTP score), all
three ratios also decreased. FLV ratio had low variability
for patients with CTP A5-B7 but was highly variable for
patients with CTP B8-C10. L/Smean ratio had higher
variability but decreased monotonically with increas-
ing score from CTP A5-B9. TLF ratio had the most
significantly negative rank correlation with CTP score
(RTLF = −0.76) compared to the other imaging parameters
(RFLV = −0.66, RL/Smean = −0.70). Note that while the inter-
quartile ranges in TLF ratio at each CTP score were nar-
row, the overall range of TLF ratios was especially high at
the interface between CTP A6 and B7. This discordance
between SC SPECT uptake measures and CTP score for
certain patients may be addressed with improved liver
function classification models.
Figure 4 illustrates absolute Spearman rank correlation
coefficients as a function of several clinical liver function
parameters, grouped by composite scoring systems (red),
individual quantitative parameters (yellow), and individ-
ual qualitative parameters (gray). FLV ratio was highly
correlated to both CTP and ALBI composite scoring
systems, but only somewhat correlated to albumin,
bilirubin, and encephalopathy. L/Smean ratio was strongly
correlated to individual quantitative components (albu-
min, bilirubin, INR) and portal hypertension but was
less correlated to the ALBI grade. TLF ratio had the
highest absolute rank correlation to the composite
scoring systems (|RTLF| = 0.64–0.76) and all components
(|RTLF| > 0.4) with the exception of splenomegaly.
The survival analysis was conducted on the patient co-
hort at a median follow-up post-treatment of 17 months
(range 1–29 months), with 12 deaths considered as
events and survivors right-censored at the last follow-up.
Among survivors, the minimum follow-up interval was
9 months and median follow-up interval was 22 months.
Patients who died presented with baseline median
TLF = 0.22 (interquartile range = 0.09–0.48). ROC analysis
for classification of overall survival yielded a cutoff value
of TLF = 0.30 (sensitivity = 0.88, specificity = 0.75). Table 2
lists the variables with statistically significant association
to overall survival (OS), including hazard ratios (HR,
95 % confidence intervals) and Cox proportional hazard
p values. TLF as a dichotomous variable (TLF > 0.30) was
most strongly associated to OS (HR = 0.08, p < 0.001).
For comparison, TLF was dichotomized by a simple
median cutoff (TLF > 0.38), under which statistical
Fig. 2 Optimal sulfur colloid SPECT/CT uptake threshold region-of-interest definition for liver imaging parameter prediction of clinical liver
function defined by Childs-Turcotte-Pugh A versus B/C class. a The receiver operator characteristic (ROC) area under the curve (AUC) is
plotted versus the percentage maximum sulfur colloid SPECT uptake threshold used to define three imaging metrics: functional liver volume (FLV)
ratio of total liver volume, mean liver-to-spleen (L/S) uptake ratio, and their product as the total liver function (TLF) ratio. b ROC curves at the optimal
SC SPECT threshold for FLV ratio, L/S mean ratio, and TLF ratios. The product of liver function magnitude and volume yields the highest accuracy for
CTP classification, with a TLF cutoff value of 0.35 having a sensitivity of 0.88 and specificity of 0.86
Table 1 Liver function imaging parameter comparison between Child-Turcotte-Pugh A versus B/C patients
CTP A (n = 16) CTP B/C (n = 14) Classification cutoff Rank sum p
Functional liver volume ratio (of liver-GTV) 0.5 (0.4–0.6) 0.3 (0.2–0.4) 0.40 6 × 10−4
Mean liver-to-spleen uptake ratio 1.4 (0.9–1.6) 0.7 (0.6–0.8) 0.88 2 × 10−4
Total liver function (FLV * L/S mean) 0.6 (0.4–0.8) 0.2 (0.1–0.3) 0.35 6 × 10−5
Median (interquartile range) values are reported for functional liver volume (FLV), mean liver-to-spleen uptake ratio, and total liver function for Child-Turcotte-Pugh
class A and B/C groups. Statistically significant differences between CTP classes were estimated by Wilcoxon rank-sum testing (α = 0.05)
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significance of univariate Cox regression was main-
tained (HR = 0.20, p = 0.02).
Multivariate Cox regression was performed by select-
ing a single imaging parameter (TLF > 0.30) with the
highest level of significance and greatest hazard ratio de-
viation from unity. This prevented inclusion of imaging
variables with high cross-correlation. The single imaging
variable was paired with a single clinical variable with
significant and substantial association to overall survival,
either CTP class or ALBI grade, which produced two
equivalent multivariate models, listed in Table 3, with
log-likelihood p < 0.001. After adjusting for clinical scor-
ing systems of liver function (CTP class, ALBI grade),
only TLF ratio above/below a threshold of 0.30 was in-
dependently associated with overall survival (model A:
HR = 0.12, 95 % CI = 0.02–0.58, p = 0.008; model B:
HR = 0.10, 95 % CI = 0.02–0.42, p = 0.002).
Discussion
Parameters of sulfur colloid SPECT/CT have potential
to measure liver function and further refine risk stratifi-
cation models for HCC patients. This investigation
Fig. 3 Box-whisker plots of sulfur colloid SPECT/CT parameter rank correlation to Child-Turcotte-Pugh score. Functional liver volume (FLV) ratio of
total liver volume correlation (a), liver-to-spleen mean uptake ratio (L/Smean) correlation (b), and total liver function (TLF) product (c) correlation to
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Fig. 4 Spearman rank correlations (absolute value) between SC SPECT parameters and clinical parameters of liver function. Functional liver
volume (FLV) ratio of total liver volume correlation (a), liver-to-spleen mean uptake ratio (L/Smean) correlation (b), and total liver function (TLF)
product (c) correlation to composite liver function classification systems (red), quantitative liver function parameters (yellow), and qualitative liver
function parameters (gray). *p < 0.01, **p < 0.001
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sought to establish SC SPECT/CT image parameters
that best correlate to clinical liver function by optimizing
the automatic thresholding of SC SPECT and correlating
relative ratios to composite and individual clinical pa-
rameters of liver function. The total liver function (TLF)
as a product of liver function magnitude (L/Smean) and
volume (FLV) was found to be the best imaging classifier
of clinical liver function as a result of having the highest
accuracy and lowest probability of a type I error in differ-
entiating CTP class. TLF was most correlated with quanti-
tative variables of liver function (albumin, bilirubin),
including independent correlation to the recent ALBI com-
posite scoring system. Correlation to qualitative clinical pa-
rameters such as portal hypertension was driven by the
liver-to-spleen ratio rather than functional liver volume.
Survival analysis revealed that TLF was associated with
overall survival after adjusting for CTP class or ALBI
grade. Following independent validation of this preliminary
finding, TLF may be considered as a candidate imaging
biomarker that complements traditional liver function clas-
sification systems, particularly in cases of discordant find-
ings. These results support further investigation on the
incorporation of complementary volumetric functional
imaging into HCC risk stratification models, which
would enable quantification of global liver function
and characterization of spatial heterogeneity in liver
function. The latter is indicated in settings where prior
liver-directed therapies may have compromised regions of
liver function. Such liver function imaging parameters
may become essential for targeted liver therapy planning
of external beam radiotherapy, radioembolization, che-
moembolization, and surgical resection.
TLF is analogous in construction to total lesion gly-
colysis from cancer imaging with FDG PET/CT, which
in several disease sites has been shown to better predict
clinical outcome and survival than imaging parameters
of uptake magnitude (SUVmean) and metabolic tumor
volume (MTV) alone [31–37]. Past investigations have
characterized liver function with SC image parameters
of magnitude (liver-to-spleen ratio) [28, 29] or size/dens-
ity (perfused hepatic mass) [26, 27], but the impact of
liver dysfunction on oncology management of HCC pa-
tients and post-therapy toxicity may be best parameterized
by integrating function with the liver volume. When
assessing our patient cohort with L/Smean and FLV alone,
eight patients (27 %) had image parameters that resulted
in different CTP classification (i.e., CTP A using L/Smean
and CTP B using FLV and vice versa), which reinforces a
complex interplay between volume and magnitude of liver
function. The TLF represents a functional liver mass that
takes into account both the density and volumetric extent
of liver function in patients. This concept of a functional
image-defined hepatic mass is intuitively in agreement
with surgical literature on the future liver remnant whose
functional changes are closely tied to post-surgical
outcomes [38–40]. TLF, when strategically paired with
quantitative clinical parameters, may prove valuable
for prediction of hepatic toxicity and long-term outcome
following validation in a larger patient cohort.
Several limitations of this investigation should be noted:
(1) sample size: the limited number of events and patients
in this preliminary survival analysis prevented definitive
multivariate Cox regression with cross-validation to power
testing on independent patient cohorts but rather sup-
ported the identification of TLF as a candidate imaging
biomarker; (2) variability in contouring of the normal liver
on CT: despite a single radiation oncologist (S.A.) defining
the anatomic liver volume region of interest, variation in-
troduced by manual contouring methods can affect the
denominator of the functional liver volume ratio; (3)
standardization of imaging protocols: while a fixed thresh-
old can be optimized for a particular imaging protocol at a
single institution, any lack of protocol standardization that
changes reconstruction algorithms or filters introduces a
bias in the estimate of image parameters and propagates
these errors across multiple institutions. Infrastructure
and resources for establishing and standardizing quantita-
tive FDG PET/CT parameters [41, 42] should also be
Table 2 Predictors of overall survival under univariate Cox
proportional hazard regression
HR 95 % CI Cox p
FLV (continuous) 0.005 0–0.64 0.02
L/Smean (>0.81) 0.19 0.05–0.42 0.008
TLF (continuous) 0.03 0.001–0.60 0.02
TLF (>0.30) 0.08 0.02–0.34 <0.001
CTP class 6.21 1.63–23.59 0.007
CTP score 1.73 1.18–2.55 0.005
ALBI grade 4.24 1.28–14.04 0.02
Hazard ratios (HR) and 95 % confidence intervals (CI) are reported along with
Cox test of significance. Continuous variables were dichotomized by a
threshold value that maximized accuracy under ROC classification with
balanced sensitivity/specificity
Table 3 Independent predictors of overall survival under
multivariate Cox proportional hazard regression
Model A HR 95 % CI Cox p
TLF (>0.30) 0.12 0.02–0.58 0.008
CTP class 2.80 0.58–13.56 0.20
Model B HR 95 % CI Cox p
TLF (>0.30) 0.10 0.02–0.42 0.002
ALBI grade 2.04 0.52–8.00 0.30
Statistically significant univariate predictors (one imaging variable, one clinical
variable) were paired. Hazard ratios (HR) and 95 % confidence intervals (CI) are
reported along with Cox test of significance. Two equivalent multivariate
regression models were generated (model A: comparison to CTP class; model
B: comparison to ALBI grade; log likelihood p < 0.001)
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adapted for quantitative imaging of liver function; (4) rela-
tive quantitation of SPECT/CT: uncertainty in modeling
of photon collimator blurring, coupled with uncertainty in
scatter and attenuation correction, have historically
limited the absolute quantitative accuracy of SPECT
imaging [43]. Advances in SPECT image reconstruction
that incorporate improved physics modeling suggest an
achievable quantitative accuracy with errors of less than
5 % [44]. This study bridges the gap between qualitative
assessment and absolute quantitation of tracer uptake by
SPECT imaging through definition of semi-quantitative
relative metrics. Future investigations will explicitly
calculate tracer uptake that has been standardized to
provide absolute quantitative accuracy and precision
characterization, which may improve quantitative imaging-
based prediction of liver function; (5) the anatomic liver
volume was defined on a radiotherapy planning CT ac-
quired during a separate patient exam whereas functional
liver parameters were defined on the sulfur colloid SPECT.
Co-registration of these images can further introduce un-
wanted variation in liver morphology between the scans
and bias the volume estimates. These sources of error in
the FLV ratio may explain the lower degree of correlation
to several clinical liver function parameters, although in
general, the imaging parameters were defined as relative
ratios to mitigate inter-patient variability in region-of-
interest definition; and lastly, (6) SC SPECT/CT images
Kupffer cells but not hepatocytes and may provide an in-
direct measure of liver function. Despite this possibility,
prior large prospective studies have shown that imaging of
Kupffer cells as measured by perfused hepatic mass inde-
pendently predicts long-term clinical outcomes in patients
with chronic liver disease [26] and is correlated with indo-
cyanine green (ICG) clearance in plasma [28], a validated
quantitative measure of global liver function [45].
Our data revealed several discordances between clinical
parameters and imaging parameters of liver function. Of
the individual clinical liver function parameters tested,
splenomegaly had the poorest correlation to imaging
parameters. The dependence of splenomegaly assessment
on spleen size could in principle affect the liver-to-spleen
ratio, but no statistical association was observed. One
possible explanation for a lack of correlation is the non-
standardized method for identifying clinical splenomegaly,
which relies on either subjective evaluation or an arbitrary
size cutoff, and is therefore prone to variability in visual
perception. Such qualitative parameters have been re-
moved from recent scoring systems like ALBI, which
further reinforces the value in quantitative functional
imaging.
Moreover, there was a subset of patients who had
discordances between liver function as defined by TLF
and clinically defined portal hypertension, a patient
characteristic that is often used by surgeons as a relative
contraindication for therapeutic surgical resection due to
concerns of post-resection-related liver failure and mor-
bidity. Of the patients with documented portal hyperten-
sion, 8 of 18 patients had TLF ratios above the cutoff
value of 0.30 associated with improved overall survival,
suggesting that up to 44 % of patients could be considered
for surgical resection depending on the extent of planned
resection [46]. This implication is hypothesis-generating
and would need to be validated in a larger cohort of pa-
tients. However, the dissociation of portal hypertension
and SC imaging as seen in our study is not entirely sur-
prising as a prior study demonstrated that the degree of
abnormality detected on SC SPECT scans was not neces-
sarily directly due to portal hypertension but related to
impaired SC extraction by the reticuloendothelial cells of
the liver [47]. To provide additional clarity in the discord-
ance between SC SPECT image parameters and clinical
liver function parameters, future work in our group will
include integrating other quantitative methods of asses-
sing liver function such as ICG clearance.
The power of SC SPECT/CT imaging resides in the
parameterization of liver function spatial heterogeneity.
With improvements in SPECT/CT quantitative accuracy
[48, 49], come opportunities to perform radiomics ana-
lysis [50] of image intensity, image texture [51], and image
shape features to characterize functional heterogeneity.
Standardization of image acquisition, reconstruction, and
segmentation prior to radiomics analysis [52, 53] will be
critical to improve reproducibility of radiomic feature esti-
mation [54, 55]. Such high dimensional imaging feature
sets will necessitate machine learning algorithms of train-
ing/(cross)-validation patient groups for feature selection
and model parameter fitting, which may lead to robust
risk stratification and outcome prediction of individual pa-
tients. It still remains unknown whether liver function
radiomics will add clinical utility relative to simple im-
aging or tissue biomarkers of liver function. Nevertheless,
prediction of both global magnitude and regional variation
in liver function may critically inform on selection and
guidance of liver-directed therapies within the scope of fu-
ture investigations.
Conclusions
Sulfur colloid SPECT/CT demonstrated utility through
correlation with clinical liver function and association
with overall survival in our preliminary investigation of
30 HCC patients undergoing definitive radiotherapy.
Following its validation as an imaging biomarker, the
total liver function (TLF) ratio may complement existing
risk classification schemes of HCC patients to promote
precise selection of patients for liver-directed therapies a
priori, including surgery, targeted intra-arterial emboli-
zations, and even liver transplantation assessment, as
well as modify radiotherapeutic strategies to reduce
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treatment-related liver morbidity and optimize tumor
control [17]. Further investigation in a larger patient co-
hort spanning a wider range of clinical liver function is
needed and underway to validate these initial findings.
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